IP Library Patent Application 16866603
Patent Application
App. No. 16/866,603

COMPOSITIONS AND METHODS FOR TREATING CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/866,603
Abstract

Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.

Claims (6)

1 . A method of treating metastatic cancer in a subject in need thereof, the method comprising:

(a) administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1; and

(b) administering to the subject a therapeutically effective amount of a PD1 antagonist, thereby treating the metastatic cancer in the subject.

2 . The method of claim 1 , wherein said cancer is pancreatic cancer.

3 . The method of claim 1 , wherein said PD1 antagonist is an anti-PD1 antibody.

4 . The method of claim 1 , wherein said cancer is pancreatic cancer, wherein said PD1 antagonist is an anti-PD1 antibody and wherein said peptide is as set forth in SEQ ID NO: 1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2021
From: PEREG, YARON
To: BIOLINERX LTD.
Reel/Frame 054991/0840 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2021
From: PELED, AMNON
To: BIOKINE THERAPEUTICS LTD.
Reel/Frame 054947/0648 →
SECURITY INTEREST Recorded Oct 27, 2020
From: BIOLINE RX LTD.
To: KREOS CAPITAL V (EXPERT FUND) L.P.
Reel/Frame 054172/0318 →